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A b s t r a c t  
Skin is one of the routes for systemic delivery of drugs through various drug delivery system. A 
transdermal Drug Delivery System (TDDS) is one of the most reliable and useful system to deliver 
drug systemically through skin. Generally medicated patch is placed on skin for delivery of 
medication through it into the blood stream. The aim of present study was to formulate and evaluate 
Palonosetron transdermal patch in vitro that could be used for antiemetic therapy. The incorporation 
ofPalonosetron a serotonin 5-HT3 antagonist drug was envisaged. The TDDS was prepared by 
solvent evaporation technique and was evaluated for organoleptic characteristics and other 
physicochemical properties Thickness, Weight variation, Drug content uniformity, Tensile strength, 
% Elongation, Folding endurance & Moisture content. The in vitro permeation study of the patch was 
carried out through KesaryChein diffusion cell as barrier membrane. Phosphate buffer pH 7.4 was 
used as dissolution medium and the temperature was maintained at 37 ± 10C. The in vitro 
permeation study of the prepared patch indicated a time dependent increase in drug release 
throughout the study. The percentage of cumulative drug release was found to be 76.25% in 24 
hours.The study shows a new approach to work in with Palonosetron. 
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Introduction 
 
A transdermal drug delivery system useful for the controlled 
systemic delivery of drugs via. skin. It is not a new concept for drug 
delivery through the skin, because many topical preparations are 
available over the years for local and systemic delivery of drugs.[1] 
But due to the low bioavailability of those delivery systems it was 
found very difficult to achieve precise drug concentration. The 
TDDS can deliver certain medications to systemic circulation 
preferably at specific rate. It also offers significant advantages such 
as avoidance of the heptic-first-pass metabolism and avoidance of 
gastrointestinal drug absorption difficulty.[2] As it comprises with a 
face membrane, the backing sheet and membrane secured together 
to form an intermediate reservoir and an impervious backing 
sheet. [3-7] 
Though the concept of TDDS is not much new but the use of this 
delivery system in the delivery of antiemetic drug is a new 
concept.[8] As vomiting/emesis is an abnormal indication of 
gastrointestinal tract, which needs an urgent medical attention. The 
oral route of medication is usually not suited and parenteral therapy 
has various limitations and drawbacks. Thus, a need arises to 
explore a possible alternate route through skin, that is, 
transdermal.[9] Although the conventional medicine, the antiemetic 
treatment has certain side effects. Hence, it needs to turn towards 
safe, effective and time tested system of delivery system. Thus, it is 
desirable to provide an effective and reliable transdermal drug 
delivery system for the treatment of vomiting and nausea. 
 
Examples of marketed transdermal drug delivery system3 
Sr. No. Therapeutic agent Marketed name (company) References 
1 Clonidine Catapres  TTS (BoehringerIngelheim) [10, 11] 
2 Estradiol Vivelle (Novartis) [6, 7, 12] 
3 Fentanyl Duragesic (Janssen) [7, 13, 14] 
4 Nicotine Prosstep (Lederie) [6, 7, 15] 
5 Testosterone Testoderm (Alza) [6, 16, 17] 
6 Nicotine Habitrol (Novartis Consumer) [15, 18] 
7 Nicotine Nicoderm CQ (Smithkline Beecham Consumer) [7, 19, 20] 
8 Nitroglycerine Transderm-Nitro (Novartis) [6, 14, 21] 
9 Scopolamine Transderm-Scop (Novartis Consumer) [3, 8, 22] 
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Objectives 
The aim of the present study was to formulate and evaluate 
antiemetic transdermal drug delivery system to provide systemic 
release. In the present formulation, incorporation of Palonsteron an 
antiemetic drug was envisaged. At the same time in vitro evaluation 
also to be done. 
Materials and methods 
The Reagent and materials of Pharma/ best possible grade were 
used as supplied by the manufacturer. PalonosetronHCl (Pharma 
Grade) Sun rise Pharma, Polyvinyl Pyrrolidone (LR) Hi-media 
pharma, Ethyl Cellulose (Pharma Grade) Colorcon Goa, Eudragit 
(LR) EvonikPharma Germany Chloroform (LR) Merck Ltd., Mumbai 
Oleic acid (LR) Ranbaxy fine chemicals Ltd., New Delhi, Dibutyl 
Phthalate (LR) Ranbaxy Fine Chemicals Ltd., New Delhi, Methanol 
(LR) Rankem, fine chemicals Limited, Mumbai, Poly Vinyl Alcohol 
(LR) Hi-media pharma. No foreign matter or impurities were found 
during inspection. 
Formulation of an Antiemetic Transdermal Patch 
The matrix-type transdermal patches containing PalonosetronHCl 
were prepared using different ratios of ethyl cellulose, 
polyvinylpryrrolidone, Eudragit and polyvinyl alcohol. The polymers 
in different ratios were dissolved in the respective solvents.[4] Then 
the drug was added slowly in the polymeric solution and stirred on 
the magnetic stirrer to obtain a uniform solution. Di-n-butyl phthalate 
and propylene glycol were used as plasticizers. Oleic acid was used 
as the penetration enhancer. Then the solution was poured on the 
Petri dish having surface area of 78.5 cm2 and dried at the room 
temperature. Then the patches were cut into 5x5 cm2 patches. Drug 
incorporated for each 2x2 cm2 patch was 14.5 mg the 
formulation.[23] 
Evaluation of Prepared Patches 
Organoleptic Characteristics. Appearance, color, clarity, flexibility, 
and smoothness of prepared patch was physically inspected. 
Thickness. The thickness of patch was measured by Vernier 
calipers. The thickness uniformity was measured at different sites 
and average was calculated.[24] 
Weight Uniformity. Sixpatches of equal size were taken and 
weighed on electronic balance to check for weight variation.[24] 
Folding Endurance. The patch was taken and folded repeatedly at 
same point till it breaks. The number of times patch could be folded 
without breaking was noted.[25] 
Moisture Content. Theprepared patch was weighed and kept in the 
desiccator containing fused calcium chloride for about 24 hours. 
After that it was taken out and weighed again.[25]The percentage of 
moisture content was calculated on the basis of the following 
formula:  
 
Percentage	of	moisture	content
= 	
Initial	weight	 − 	Final	weight
Final	weight
	× 100 
 
Drug Content. The patch was dissolved in methanol and the 
remaining volume was made up with distilled water to 100mL.Then 
the solution was filtered and the absorbance of the solution was 
taken at 304 nm and concentration was calculated. 
Drug Content. The patch was dissolved in methanol and the 
remaining volume was made up with distilled water to 100mL.Then 
the solution was filtered and the absorbance of the solution was 
taken at 304 nm and concentration was calculated.[25] 
In Vitro Permeation Study of Patch. 
Egg shell membrane was used for the in vitro permeation study of 
the prepared transdermal patch because the egg shell membrane 
resembles stratum corneum of human which consists of keratin 
mainly in it.[26] The membrane was prepared accordingly reported 
by Shah etal before use.[27]During the whole experiment37 ± 10C 
was maintained to provide a skin surface temperature on the outer 
jacket of water of the cell, and the pH 7.4 was maintained used as 
dissolution medium. After that the patch was cut in 5 × 5mm2 piece 
which was taken and applied over the mounted membrane in 
diffusion cell and the samples were withdrawn from different 
compartment at regulated intervals. The sampling schedule was at 
0, 0.5, and 1 hr for the first hour of release and then it was at every 
hour interval till 6thhour of release.After that the whole system was 
kept in its normal position overnight and then next day reading was 
taken at 24thhour.One mL of the receptor solution was collected as 
sample each time and simultaneously one mL of phosphate buffer 
solution was added back to the receptor cell for maintaining the 
same initial volume of the receptor cell solution. The collected 
samples were analysed using UV-Vis spectrophotometer.[24] 
Results and Discussion  
Vomiting/emesis is an emergent situation for which oral route of 
medication is usually not suited, especially in motion sickness 
condition where oral or parenteral route of administration is not 
admissible. However various antiemetic formulations are available 
through oral route but becomes useless during continuous vomiting. 
So, a pharmaceutical strategy was envisaged to generate significant 
scientific data by designing and developing a novel, safe, 
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noninvasive, and patient-friendly dosage form, that is, transdermal 
drug delivery dosage form.For the design and development of 
antiemetic drug into novel dosage form. The rationale behind 
formulation is to provide better patient compliance with reduced 
dose. 
 
 
Figure 1: Sample of prepared transdermal antiemetic patch 
 
Table 1: Standard calibration curve of PalonosetronHCl 
Sr. No. Concentration (μg/ml) Absorbance 
1 0 0 
2 4 0.277 
3 6 0.361 
4 8 0.482 
5 10 0.58 
6 12 0.60 
7 14 0.823 
8 16 0.928 
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Graph 1: Calibration curve of Palonosetron 
Initially a standard calibration curve for Palonosetron was prepared. 
The absorbance values are given in Table 1. Using concentration 
and absorbance data, Beer and Lambert’s plot was obtained. The 
plot is shown in Graph 1. 
Organoleptic Characteristics 
The prepared patches were slightly opaque, pale whitecolored, 
jellified preparations showing good flexibility and smoothness as 
given in Table 2. A sample of prepared patch is shown in Figure 2.  
Thickness 
The mean thickness of prepared patches was 0.61 ± 0.02608mm as 
given in Table 3. 
Weight Uniformity. The mean weight of prepared patches was 
0.26217±0.00248gm as given in Table3. 
Folding Endurance. The mean folding endurance of prepared 
patches was 78.66667±1.21106as given in Table 3.  
Moisture Content. The mean moisture content of prepared patches 
was 4.86833±0.0694% as given in Table 3.  
Drug Content. The mean drug content of the prepared patches was 
0.29267±0.0055mg in w/w ratio with the weight of patch as given in 
Table 3.  
In Vitro Permeation Study of Patch. The in vitro permeation studies 
of the prepared transdermal patches indicated a time dependent 
increase throughout the study as shown in Figure 4. The drug 
release from patches was rapid during first hour and it slowed down 
thereafter. The percentage of drug release was 22.60% after30 
minutes which further increased to 29.78% in one hour. The 
cumulative drug release increased gradually and reached 58.65% in 
6 hours. Finally, at the end of study, the cumulative drug release 
reached a remarkable peak, that is, 76.25% in 24 hours, as given in 
Table 4. 
 
Table 2: Oragnoleptic Characteristics of Transdermal Patch 
S. No. Physical Characteristics Finding 
1 Color Pale white 
2 Appearance Jelly 
3 Smoothness Good 
4 Clarity Opaque 
5 Flexibility Excellent 
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Table 3: Physical characteristics of patch 
S. No. Thickness (mm) Weight (gm) Folding endurance 
Moisture content 
(%) 
Drug Content 
(mg) 
1 0.64 0.261 80 4.98 0.298 
2 0.57 0.265 78 4.78 0.285 
3 0.61 0.263 77 4.82 0.291 
4 0.62 0.258 79 4.85 0.296 
5 0.59 0.262 78 4.90 0.298 
6 0.63 0.264 80 4.88 0.288 
Mean±SD 0.61±0.02608 0.26217±0.00248 78.66667±1.21106 4.86833±0.0694 0.29267±0.0055 
 
Table 4: In vitro permeation study of patch 
S. No. Collection Time (in hrs) Concentration (ug/ml) %CDR 
1 0 0 0 
2 0.5 6.428 22.6 
3 1 8.26 29.78 
4 2 10.245 36.45 
5 3 12.590 44.35 
6 4 15.856 47.35 
7 5 18.355 52.95 
8 6 20.245 58.65 
9 12 21.865 64.38 
10 24 31.585 76.25 
 
Conclusion  
According to the current demand in pharmaceuticalscenario, it was 
felt that new drug delivery system is necessary to handle the 
vomiting condition especially in motion sickness where if a patient 
needs to travel for more than 24hrs. And the unavailability of 
dosage form which can provide relief for more than 24hrs, 
transdermal patch shall be a better option than oral dosage form. 
Because the patch was found to be stable, controlled release, with 
longer duration of action without any signs of skin irritation. The 
study shows a novel approach in pharmaceutics to use various 
antiemetic drugs with other dosage forms. Further, a clinical study is 
warranted to evaluate therapeutic efficacy of current dosage form. 
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